Embryonic Stem Cell News and Research

RSS

ACT files IND application to initiate Phase I/II study for Dry AMD

Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).

30 Nov 2010

BioTime, CIRM enter agreement for GMP-grade hES cell lines

BioTime, Inc. today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation.

29 Nov 2010

EHNA treatment blocks spontaneous differentiation of stem cells

Human embryonic stem cells have enormous potential for use in pharmaceutical development and therapeutics; however, to realize this potential there is a requirement for simple and reproducible cell culture methods that provide adequate numbers of cells of suitable quality.

26 Nov 2010

Embryonic stem cell research has not made good on taxpayer investment

In 2004 Robert Klein, chairman of the California Institute of Regenerative Medicine (CIRM), helped pass Proposition 71, establishing the CIRM with a state taxpayer-funded $3 billion budget for ten years. The measure was passed with promises of affordable cures for virtually all diseases, cures specifically from embryonic stem cells and cloning, as well as tremendous financial payback for the citizens of California. The Los Angeles Times recently noted that Klein plans to seek up to $3 billion more from state taxpayers for his stem cell fiefdom.

25 Nov 2010

Stem cell trial for eye disease receives FDA approval

The second clinical trial involving stem cells from human embryonic cells has received the go-ahead. The news came from Advanced Cell Technology Inc. this Monday. The company announced that the U.S. Food and Drug Administration has cleared the way for its Phase I/II trial of retinal cells for patients with Stargardt’s macular dystrophy, a childhood version of macular degeneration.

22 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

Research indicates possible danger of cancerous tissue development by using stem cells

Research work carried out at the Hebrew University of Jerusalem arouses a cautionary warning in the growing field of the development of stem cells as a means for future treatment of patients through replacement of diseased or damaged tissues by using the patient's own stem cells. The research indicates a possible danger of cancerous tissue development in the use of such cells.

22 Nov 2010

Reprogrammed amniotic fluid cells can generate iPS cells

Reprogrammed amniotic fluid cells can generate all types of body cells. High hopes rest on stem cells: one day, they may be used to treat many diseases. To date, embryos are the main source of these cells, but this raises ethical problems. Scientists at the Max Planck Institute for Molecular Genetics in Berlin have now managed to convert amniotic fluid cells into pluripotent stem cells.

20 Nov 2010

Stem cells for stroke: Clinical trial commences

Researchers have started the world’s first clinical trial of stem cells to treat stroke victims in Glasgow. The trial is undertaken by ReNeuron, a Guildford-based biotech company and started this weekend with an elderly man receiving an injection of 2 million stem cells into his brain. It received final approval to go ahead this year.

16 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

New findings shed light on biology of neuropsychiatric diseases

The biggest surprise to me was that we could rescue the autistic phenotype [in the human cells] to something close to normal, said Alysson Muotri of the University of California San Diego.

12 Nov 2010

Researchers study Rett neurons in a Petri dish

A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.

12 Nov 2010

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

The Genetics Policy Institute (GPI) today announced the launch of a new advocacy coalition of 30 organizations to foster public awareness and advance the cause of embryonic stem cell research in the United States.

12 Nov 2010

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI).

11 Nov 2010

TRPM7 protein plays a key role in maintenance of magnesium homeostasis

An international team led by researchers at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School has published new findings that demonstrate how a specific protein controls the body's ability to balance magnesium levels. Magnesium is an essential element for good health and is critical to more than 300 biochemical reactions that occur in the body.

8 Nov 2010

Skin to blood transformation in the lab

In a new study scientists have successfully transformed human skin cells into blood without first being sent through a primordial, stem-cell-like state. The findings were published online in the journal Nature. Earlier work has shown that fibroblast cells from mouse skin, treated with the right cocktail of chemicals, can be transformed into neurons and heart muscle. This is a first with human cells.

7 Nov 2010

Type of contrast agent influences changes in stem cell proliferation

When researchers tested three different labeling agents on three different stem cell populations to determine what effect the labeling agents had on stem cell phenotype, biological behavior and migration abilities, they found changes in stem cell proliferation depending on the type of contrast agent used.

2 Nov 2010

New iPSC cell lines could help in treating patients with lung diseases

A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could possibly lead to new treatments for these debilitating diseases.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

Embryonic Stem Cell News and Research

ACT files IND application to initiate Phase I/II study for Dry AMD

BioTime, CIRM enter agreement for GMP-grade hES cell lines

EHNA treatment blocks spontaneous differentiation of stem cells

Embryonic stem cell research has not made good on taxpayer investment

Stem cell trial for eye disease receives FDA approval

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Research indicates possible danger of cancerous tissue development by using stem cells

Reprogrammed amniotic fluid cells can generate iPS cells

Stem cells for stroke: Clinical trial commences

BioTime third quarter total revenues increase 82% to $815,284

New findings shed light on biology of neuropsychiatric diseases

Researchers study Rett neurons in a Petri dish

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

Nutech Mediworld founder presents clinical study results of hESC therapy in patients with spinal cord injury

TRPM7 protein plays a key role in maintenance of magnesium homeostasis

Skin to blood transformation in the lab

Type of contrast agent influences changes in stem cell proliferation

New iPSC cell lines could help in treating patients with lung diseases

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Researchers create new high-content assay to increase human embryonic stem cell survival

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News